PT-141 (Bremelanotide) vs VIP (Vasoactive Intestinal Peptide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Full details →

VIP (Vasoactive Intestinal Peptide)

VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.

Full details →

Side-by-Side Comparison

AspectPT-141 (Bremelanotide)VIP (Vasoactive Intestinal Peptide)
MechanismPT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system.Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects.
Typical DosageFDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition.
AdministrationSubcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light.
Side EffectsCommon side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses.
Best For

Key Differences

Unique to PT-141 (Bremelanotide):

Unique to VIP (Vasoactive Intestinal Peptide):

Ready to Learn More?